Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Corvus Pharmaceuticals ( (CRVS) ) has shared an update.
On May 14, 2026, Corvus Pharmaceuticals reported final results from a randomized, blinded, placebo-controlled Phase 1 trial of oral ITK inhibitor soquelitinib in 72 patients with moderate-to-severe atopic dermatitis who had failed prior therapies, including systemic agents. The data, presented at the Society for Investigative Dermatology annual meeting in Chicago, showed a favorable safety profile, dose-dependent efficacy and comparable responses in treatment-resistant patients.
At the 200 mg twice-daily dose, 50% and 75% of patients in cohorts 3 and 4, respectively, achieved at least a 75% improvement in EASI scores, with durable disease control persisting 30 to 90 days after treatment cessation and no rebound or need for rescue medication compared with published experience for current systemic options. Biomarker analyses indicated that soquelitinib selectively inhibits ITK, reduces Th2/Th17 activity, increases persistent Treg cells and modulates JAK-STAT signaling, supporting a mechanism consistent with prompt clinical responses, prolonged drug-free remissions and safety without systemic immunosuppression, which could strengthen Corvus’s position in the competitive atopic dermatitis market if confirmed in later-stage trials.
The most recent analyst rating on (CRVS) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Corvus Pharmaceuticals stock, see the CRVS Stock Forecast page.
Spark’s Take on CRVS Stock
According to Spark, TipRanks’ AI Analyst, CRVS is a Neutral.
The score is held down primarily by weak financial performance (no revenue, widening losses, and ongoing cash burn). Offsetting this, the earnings call highlighted promising clinical data and a materially strengthened cash runway into Q2 2028. Technicals are neutral overall and valuation is constrained by losses and no dividend support.
To see Spark’s full report on CRVS stock, click here.
More about Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oral immunotherapies, including the ITK inhibitor soquelitinib, targeting immune pathways involved in inflammatory and autoimmune diseases such as moderate-to-severe atopic dermatitis. The company’s research centers on modulating T cell signaling to rebalance the immune system without broad immunosuppression.
Average Trading Volume: 1,269,998
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.34B
For an in-depth examination of CRVS stock, go to TipRanks’ Overview page.